Cepheid (CPHD) Has Room to Run Higher, UBS Says; PT Lifted
Tweet Send to a Friend
UBS analyst Daniel Arias boosted his price target on Buy-rated Cepheid (NASDAQ: CPHD) from $44 to $48 saying there is ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
